Literature DB >> 24843152

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Patrick J Lupardus1, Mark Ultsch2, Heidi Wallweber2, Pawan Bir Kohli3, Adam R Johnson3, Charles Eigenbrot1.   

Abstract

Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons. JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism. Here, we report the 2.8-Å structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form. We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface. Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro. These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.

Entities:  

Keywords:  JAK1; JAK3

Mesh:

Substances:

Year:  2014        PMID: 24843152      PMCID: PMC4050602          DOI: 10.1073/pnas.1401180111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Jaks and cytokine receptors--an intimate relationship.

Authors:  Claude Haan; Stephanie Kreis; Christiane Margue; Iris Behrmann
Journal:  Biochem Pharmacol       Date:  2006-04-27       Impact factor: 5.858

2.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

Authors:  Isabelle S Lucet; Emmanuelle Fantino; Michelle Styles; Rebecca Bamert; Onisha Patel; Sophie E Broughton; Mark Walter; Christopher J Burns; Herbert Treutlein; Andrew F Wilks; Jamie Rossjohn
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

3.  JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

Authors:  Judith Staerk; Anders Kallin; Jean-Baptiste Demoulin; William Vainchenker; Stefan N Constantinescu
Journal:  J Biol Chem       Date:  2005-10-19       Impact factor: 5.157

4.  Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

Authors:  Lyndal Kearney; David Gonzalez De Castro; Jenny Yeung; Julia Procter; Sharon W Horsley; Minenori Eguchi-Ishimae; Caroline M Bateman; Kristina Anderson; Tracy Chaplin; Bryan D Young; Christine J Harrison; Helena Kempski; Chi Wai E So; Anthony M Ford; Mel Greaves
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

5.  JAK mutations in high-risk childhood acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Richard C Harvey; J Racquel Collins-Underwood; Brenda A Schulman; Letha A Phillips; Sarah K Tasian; Mignon L Loh; Xiaoping Su; Wei Liu; Meenakshi Devidas; Susan R Atlas; I-Ming Chen; Robert J Clifford; Daniela S Gerhard; William L Carroll; Gregory H Reaman; Malcolm Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

6.  Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

Authors:  Amos Gaikwad; Cassia L Rye; Meenakshi Devidas; Nyla A Heerema; Andrew J Carroll; Shai Izraeli; Sharon E Plon; Giuseppe Basso; Andrea Pession; Karen R Rabin
Journal:  Br J Haematol       Date:  2008-12-20       Impact factor: 6.998

7.  Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.

Authors:  Tomohiko Sato; Tsutomu Toki; Rika Kanezaki; Gang Xu; Kiminori Terui; Hirokazu Kanegane; Masayoshi Miura; Souichi Adachi; Masahiro Migita; Shingo Morinaga; Takahide Nakano; Mikiya Endo; Seiji Kojima; Hitoshi Kiyoi; Hiroyuki Mano; Etsuro Ito
Journal:  Br J Haematol       Date:  2008-04-07       Impact factor: 6.998

8.  Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

Authors:  Alexandra Dusa; Judith Staerk; Joanne Elliott; Christian Pecquet; Hélène A Poirel; James A Johnston; Stefan N Constantinescu
Journal:  J Biol Chem       Date:  2008-03-06       Impact factor: 5.157

9.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.

Authors:  Dani Bercovich; Ithamar Ganmore; Linda M Scott; Gilad Wainreb; Yehudit Birger; Arava Elimelech; Chen Shochat; Giovanni Cazzaniga; Andrea Biondi; Giuseppe Basso; Gunnar Cario; Martin Schrappe; Martin Stanulla; Sabine Strehl; Oskar A Haas; Georg Mann; Vera Binder; Arndt Borkhardt; Helena Kempski; Jan Trka; Bella Bielorei; Smadar Avigad; Batia Stark; Owen Smith; Nicole Dastugue; Jean-Pierre Bourquin; Nir Ben Tal; Anthony R Green; Shai Izraeli
Journal:  Lancet       Date:  2008-09-19       Impact factor: 79.321

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  65 in total

1.  Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.

Authors:  Cristina Pérez; Julia González-Rincón; Arantza Onaindia; Carmen Almaráz; Nuria García-Díaz; Helena Pisonero; Soraya Curiel-Olmo; Sagrario Gómez; Laura Cereceda; Rebeca Madureira; Mercedes Hospital; Dolores Suárez-Massa; José L Rodriguez-Peralto; Concepción Postigo; Alicia Leon-Castillo; Carmen González-Vela; Nerea Martinez; Pablo Ortiz-Romero; Margarita Sánchez-Beato; Miguel Á Piris; José P Vaqué
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.

Authors:  Kirsten Canté-Barrett; Joost C M Uitdehaag; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

3.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

4.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Authors:  Sandrine Degryse; Simon Bornschein; Charles E de Bock; Emilie Leroy; Marlies Vanden Bempt; Sofie Demeyer; Kris Jacobs; Ellen Geerdens; Olga Gielen; Jean Soulier; Christine J Harrison; Stefan N Constantinescu; Jan Cools
Journal:  Blood       Date:  2017-11-29       Impact factor: 22.113

5.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

6.  JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients.

Authors:  Matthew K Stein; Lindsay K Morris; Mike G Martin
Journal:  Pathol Oncol Res       Date:  2018-06-03       Impact factor: 3.201

Review 7.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

8.  Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Authors:  E Waanders; B Scheijen; M C J Jongmans; H Venselaar; S V van Reijmersdal; A H A van Dijk; A Pastorczak; R D A Weren; C E van der Schoot; M van de Vorst; E Sonneveld; N Hoogerbrugge; V H J van der Velden; B Gruhn; P M Hoogerbrugge; J J M van Dongen; A Geurts van Kessel; F N van Leeuwen; R P Kuiper
Journal:  Leukemia       Date:  2016-10-13       Impact factor: 11.528

Review 9.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.

Authors:  Olli Silvennoinen; Stevan R Hubbard
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

10.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.

Authors:  John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.